Article
Oncology
Yaxiao Lu, Jingwei Yu, Wenchen Gong, Liping Su, Xiuhua Sun, Ou Bai, Hui Zhou, Xue Guan, Tingting Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Xianhuo Wang, Huilai Zhang
Summary: The study aimed to evaluate the prognostic value of peripheral blood T lymphocyte subsets in FL patients and develop a predictive model (ICPI) for PFS. The ICPI demonstrated improved prognostic performance and could guide personalized therapy for patients treated with R-CHOP/CHOP chemotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Naree Warnnissorn, Nonglak Kanitsap, Pimjai Niparuck, Paisarn Boonsakan, Prapasri Kulalert, Wasithep Limvorapitak, Lantarima Bhoopat, Supawee Saengboon, Pichika Chantrathammachart, Teeraya Puavilai, Suporn Chuncharunee
Summary: This study aimed to validate and compare the effectiveness of IPI, R-IPI, and NCCN-IPI in predicting 2-year progression-free survival of DLBCL patients treated with R-CHOP. The results showed that NCCN-IPI was the best prognostic index, but the prognostic model for DLBCL patients treated with R-CHOP still needs updating or integrating biomarkers to improve discrimination.
Article
Oncology
Maike Stegemann, Sophy Denker, Clemens A. Schmitt
Summary: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma. The standard of care (SOC) for newly diagnosed DLBCL patients is the R-CHOP immunochemotherapy protocol, which can cure approximately two-thirds of patients. However, due to the molecular heterogeneity of DLBCL, many patients eventually succumb to the disease despite improved next-line options. Therefore, enhancing the efficacy of first-line treatment is critical for improving outcomes in DLBCL.
Article
Oncology
Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, David W. Scott, Qingyuan Zhang, Wojciech Jurczak, Muhit Ozcan, Xiaonan Hong, Jun Zhu, Jie Jin, David Belada, Juan Miguel Bergua, Francesco Piazza, Heidi Mocikova, Anna Lia Molinari, Dok Hyun Yoon, Federica Cavallo, Monica Tani, Kazuhito Yamamoto, Koji Izutsu, Koji Kato, Myron Czuczman, Sarah Hersey, Adrian Kilcoyne, Jacqueline Russo, Krista Hudak, Jingshan Zhang, Steve Wade, Thomas E. Witzig, Umberto Vitolo
Summary: The ROBUST study aimed to compare the efficacy of lenalidomide plus R-CHOP with placebo/R-CHOP in previously untreated ABC-type DLBCL. While the primary end point of progression-free survival (PFS) was not met in all patients, there were trends favoring R2-CHOP over placebo/R-CHOP in patients with higher-risk disease. The safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Dermatology
Ji Yun Lee, Minsu Kang, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Kyoung-Ho Song, Eu Suk Kim, Hong Bin Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong-Seok Lee, Jeong-Ok Lee
Summary: This study found that PCP prophylaxis is highly effective in preventing PCP infection in DLBCL patients undergoing R-CHOP treatment, which can guide prevention strategies for PCP.
Article
Oncology
Yu Zhang, Jingjing Xiang, Xianfu Sheng, Ni Zhu, Shu Deng, Junfa Chen, Lihong Yu, Yan Zhou, Chenjun Lin, Jianping Shen
Summary: The study shows that CHOP and R-CHOP treatments potentiate the anti-tumor properties of macrophages by suppressing AKT signaling, with GM-CSF further enhancing their effects.
CANCER CELL INTERNATIONAL
(2021)
Article
Hematology
Guillermo Villacampa, Rodrigo Dienstmann, Francesc Bosch, Pau Abrisqueta
Summary: A systematic review and meta-analysis found that adding molecular targeted agents to R-CHOP in DLBCL patients may only slightly improve progression-free survival (PFS). Younger patients may benefit more, but with a higher rate of adverse events.
ANNALS OF HEMATOLOGY
(2021)
Article
Hematology
D. Al-Sarayfi, M. Brink, M. E. D. Chamuleau, R. Brouwer, R. S. van Rijn, D. Issa, W. Deenik, G. Huls, R. Mous, J. S. P. Vermaat, A. Diepstra, J. M. Zijlstra, T. van Meerten, M. Nijland
Summary: An attenuated chemo-immunotherapy strategy called R-miniCHOP was introduced as a treatment option for elderly frail patients with diffuse large B-cell lymphoma (DLBCL) in the Netherlands. Although it is more tolerable, the reduction of chemotherapy in R-miniCHOP may negatively affect survival compared to the standard treatment R-CHOP. The study found that patients treated with R-miniCHOP had inferior survival outcomes compared to those treated with R-CHOP.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Annalisa Arcari, Lugi Rigacci, Alessandra Tucci, Benedetta Puccini, Sara Veronica Usai, Federica Cavallo, Alberto Fabbri, Monica Balzarotti, Sabrina Pelliccia, Stefano Luminari, Elsa Pennese, Vittorio Ruggero Zilioli, Abdurraouf Mokhtar Mahmoud, Gerardo Musuraca, Dario Marino, Roberto Sartori, Barbara Botto, Guido Gini, Manuela Zanni, Stefan Hohaus, Giuseppe Tarantini, Leonardo Flenghi, Monica Tani, Alice Di Rocco, Michele Merli, Daniele Vallisa, Chiara Pagani, Luca Nassi, Daniela Dessi, Simone Ferrero, Emanuele Cencini, Patrizia Bernuzzi, Caterina Mammi, Luigi Marcheselli, Valentina Tabanelli, Michele Spina, Francesco Merli
Summary: R-CHOP is the commonly used treatment for DLBCL, but it has cardiotoxicity in older patients. Substituting doxorubicin with non-PEGylated liposomal doxorubicin (R-COMP) may reduce cardiac events, but its efficacy has not been proven in prospective trials. This study suggests that R-COMP is a potential treatment for older DLBCL patients with intermediate or high-risk EPI, even in the presence of baseline cardiopathy.
Review
Oncology
Oren Pasvolsky, Alon Rozental, Pia Raanani, Anat Gafter-Gvili, Ronit Gurion
Summary: Adding another drug to R-CHOP as frontline treatment for DLBCL did not significantly improve overall survival, but did show significant advantages in disease control. The addition of lenalidomide to R-CHOP may have the most notable impact on treatment efficacy, although it also comes with increased risk of adverse events. Further research may help identify subgroups that could benefit the most from augmenting standard R-CHOP.
Review
Hematology
Brian T. Hill, Brad Kahl
Summary: Diffuse large B-cell lymphoma (DLBCL) is a collection of malignancies with distinct molecular features. Recent studies have identified at least five different subtypes of DLBCL, further categorizing previously recognized subtypes. Clinical trials using novel therapeutic agents to improve outcomes have been largely unsuccessful.
EXPERT REVIEW OF HEMATOLOGY
(2022)
Review
Hematology
Edward J. Bataillard, Chan Yoon Cheah, Matthew J. Maurer, Arushi Khurana, Toby A. Eyre, Tarec Christoffer El-Galaly
Summary: The dilemma of using full or reduced dose intensity of R-CHOP in elderly patients with DLBCL was studied through a systematic review. Lower dose intensity was associated with poorer survival outcomes in most studies, especially in patients aged <80 years. However, elderly patients aged >= 80 years did not show consistent impact on survival outcomes with reduced dose intensity, suggesting full-dose R-CHOP may be more appropriate in this age group. Additional DI-specific randomized trials are needed for further confirmation.
Article
Oncology
Theodoros P. Vassilakopoulos, Michail Michail, Sotirios Papageorgiou, Georgia Kourti, Maria K. Angelopoulou, Fotios Panitsas, Sotirios Sachanas, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Eleftheria Hatzimichael, Maria Kotsopoulou, Maria Dimou, Eleni Variamis, Dimitrios Boutsis, Evangelos Terpos, Maria N. Dimopoulou, Stamatios Karakatsanis, Eurydiki Michalis, George Karianakis, Pantelis Tsirkinidis, Chryssa Vadikolia, Christos Poziopoulos, Anna Pigaditou, Effimia Vrakidou, Theophanis Economopoulos, Lydia Kyriazopoulou, Marina P. Siakantaris, Marie-Christine Kyrtsonis, Argyris Symeonidis, Konstantinos Anargyrou, Maria Papaioannou, Evdoxia Hatjiharissi, Elissavet Vervessou, Maria Tsirogianni, Maria Palassopoulou, Gabriella Gainaru, Ekaterini Stefanoudaki, Panayiotis Zikos, Panayiotis Tsirigotis, Gerasimos Tsourouflis, Theodora Assimakopoulou, Pavlina Konstantinidou, Helen A. Papadaki, Katerina Megalakaki, Meletios-Athanasios Dimopoulos, Vassiliki Pappa, Themis Karmiris, Paraskevi Roussou, Panayiotis Panayiotidis, Kostas Konstantopoulos, Gerassimos A. Pangalis
Summary: Clinical prognostic factors play a significant role in predicting the outcome of patients with PMLBCL treated with R-CHOP, with two models performing better than established risk scores. These models can help in identifying high-risk subgroups and determining the need for more intensive treatment.
Article
Oncology
Sushanth Gouni, Paolo Strati, Gokce Toruner, Akanksha Aradhya, Ralf Landgraf, Daniel Bilbao, Francisco Vega, Nitin Kumar Agarwal
Summary: The study found that the concurrent use of statins with R-CHOP chemotherapy regimen significantly increased the complete remission rate in patients with naive-treated DLBCL. Patients treated with medium or high intensity statins alongside R-CHOP had a significantly higher complete remission rate and progression-free survival compared to those treated with R-CHOP alone.
LEUKEMIA & LYMPHOMA
(2022)
Article
Hematology
Ciara L. Freeman, Kerry J. Savage, Diego R. Villa, David W. Scott, Line Srour, Alina S. Gerrie, Maura J. Brown, Graham W. Slack, Pedro Farinha, Brian Skinnider, James Morris, Francois Benard, Christina Aquino-Parsons, Andrea Lo, Tom Pickles, Don C. Wilson, Petter Tonseth, Joseph M. Connors, Laurie H. Sehn
Summary: This study analyzed patients with advanced-stage DLBCL who received at least 6 cycles of R-CHOP treatment, with PET-guided selective administration of consolidative RT showing similar outcomes in PET-POS patients to those of PET-NEG patients. The use of F-18-fluorodeoxyglucose-PET can reliably guide selective administration of consolidative RT, even in patients with initially bulky disease.
